Category: Treatment


Acral Melanoma & Adjuvant Therapy – One Patient’s Decision

By Cody R. Barnett, MRA Director of Communications | 23 July 2019 In Melanoma Stories, Treatment

When David was diagnosed with Stage 3 acral melanoma he faced a major decision. The surgery to remove it was successful - but should he move forward with adjuvant therapy to reduce the risk of it returning? Learn more about the benefits - and risks - of this approach and read what David decided.

Read More


New Models for Testing Melanoma Drugs and Vaccines

15 July 2019 In Science, Treatment

Before experimental drugs and vaccines can ever be tested in people, they must first be studied in models of the disease. These models allow researchers to investigate scientific questions that they cannot answer using people due to unknown risks.

Read More


Can We Combine Immunotherapy and Targeted Therapy for Better Results?

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 25 June 2019 In Science, Treatment

Researchers are now considering how to build upon the success of immune-based and targeted therapies to help even more patients live longer, healthier lives. This month, several studies reported on efforts to combine PD-1 based immunotherapy with BRAF/MEKi targeted therapy to form the first ‘triple combos’ in melanoma.

Read More


Resisting Resistance

14 June 2019 In Science, Treatment

For too many patients, the incredible responses they experience from targeted and immunotherapies don't last. Resistance is a real challenge. At the MRA 2019 Scientific Retreat, several researchers reported on research funded by MRA to identify new ways to combat drug resistance, including a number of strategies that are already being tested in the clinic.

Read More


Fighting For Her Life with a Clinical trial

By Cody R. Barnett, MRA Director of Communications | 7 June 2019 In Melanoma Stories, Science, Treatment

Colleen Wittoesch was a regular volunteer at MD Anderson Cancer Center. She came to the hospital every week to help out and spend time with patients and families in the melanoma clinic for going on seven years. Little did she know that in 2016 she too would walk through the clinic doors as a patient.

Read More


Highlights from the 2019 Scientific Retreat

30 May 2019 In Allies & Partnerships, Events, Melanoma Stories, News, Prevention, Science, Treatment

Over the course of three days, MRA convened over 300 people from across the melanoma research community: patients, doctors, researchers, industry, and government. Participants discussed everything from new treatment approaches such as RNA-based vaccines, strategies to fight back against treatment resistance, and hurdles to testing neo-adjuvant therapies in melanoma.

Read More


Clinical Trials to Watch: Turning Cold Tumors Hot

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 15 May 2019 In Science, Treatment

We know that the billions of bacteria that live in our bodies can impact the way we respond to immunotherapy, but can we harness this help more patients respond these life-saving drugs?

Read More


Melanoma Vaccines Show Promise

14 April 2019 In Science, Treatment

While immunotherapy has transformed way melanoma is treated, about half of patients still do not respond. Researchers are pursuing multiple strategies to understand why this happens and to develop strategies to jumpstart a response. One approach showing promise in early clinical trials, comes in the form of new personalized vaccines being developed by Ugur Sahin of Johannes Gutenberg-Universität Mainz and BioNTech.

Read More


What’s Next for the Microbiome in Melanoma?

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 11 April 2019 In Science, Treatment

We know that the billions of bacteria that live in our bodies can impact the way we respond to immunotherapy, but can we harness this help more patients respond these life-saving drugs?

Read More


Overcoming Targeted Therapy Resistance

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 22 February 2019 In Science, Treatment

Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.

Read More


Login

×